# Artiva Biotherapeutics, Inc.: financial statements, quarterly

ARTV · Nasdaq · CIK 1817241 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/artv.md) · [Financials](/companies/artv/financials.md) · [Filings](/companies/artv/filings.md) · [Insiders](/companies/artv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/artv/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [26.7](/filings/0000950170-24-125382.md) | [1.8 d](/filings/0000950170-25-043837.md) | [0.3](/filings/0000950170-25-066421.md) | [0.0 d](/filings/0000950170-25-104045.md) | [0.0 d](/filings/0001193125-25-275872.md) | [0.0 d](/filings/0001193125-26-100135.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [13.1](/filings/0000950170-24-125382.md) | [11.2 d](/filings/0000950170-25-043837.md) | [11.2](/filings/0000950170-25-066421.md) | [12.3](/filings/0000950170-25-104045.md) | [13.5](/filings/0001193125-25-275872.md) | [13.3 d](/filings/0001193125-26-100135.md) | [17.1](/filings/0001193125-26-213242.md) | [17.9](/filings/0001193125-26-338029.md) | [17.6](/filings/0001193125-25-275872.md) | [17.0 d](/filings/0001193125-26-100135.md) | [19.3](/filings/0001193125-26-213242.md) | [21.9](/filings/0001193125-26-338029.md) |
| Operating income | $m | [10.8](/filings/0000950170-24-125382.md) | [(12.0) d](/filings/0000950170-25-043837.md) | [(14.5)](/filings/0000950170-25-066421.md) | [(16.2)](/filings/0000950170-25-104045.md) | [(18.3)](/filings/0001193125-25-275872.md) | [(18.3) d](/filings/0001193125-26-100135.md) | [(22.2)](/filings/0001193125-26-213242.md) | [(22.8)](/filings/0001193125-26-338029.md) | [(22.9)](/filings/0001193125-25-275872.md) | [(21.9) d](/filings/0001193125-26-100135.md) | [(24.4)](/filings/0001193125-26-213242.md) | [(26.9)](/filings/0001193125-26-338029.md) |
| Net income | $m | [11.3](/filings/0000950170-24-125382.md) | [(12.0) d](/filings/0000950170-25-043837.md) | [(14.0)](/filings/0001193125-25-275872.md) | [(17.8)](/filings/0001193125-25-275872.md) | [(17.5)](/filings/0001193125-25-275872.md) | [(16.1) d](/filings/0001193125-26-100135.md) | [(20.3)](/filings/0001193125-26-338029.md) | [(21.3)](/filings/0001193125-26-338029.md) | [(21.5)](/filings/0001193125-25-275872.md) | [(20.8) d](/filings/0001193125-26-100135.md) | [(23.5)](/filings/0001193125-26-338029.md) | [(25.0)](/filings/0001193125-26-338029.md) |
| Diluted EPS | $ per share | [1.62](/filings/0000950170-24-125382.md) | not reported | [(17.24)](/filings/0000950170-25-066421.md) | [(22.00)](/filings/0000950170-25-104045.md) | [(0.92)](/filings/0001193125-25-275872.md) | not reported | [(0.83)](/filings/0001193125-26-213242.md) | [(0.87)](/filings/0001193125-26-338029.md) | [(0.88)](/filings/0001193125-25-275872.md) | not reported | [(0.95)](/filings/0001193125-26-213242.md) | [(0.63)](/filings/0001193125-26-338029.md) |
| Basic EPS | $ per share | [13.98](/filings/0000950170-24-125382.md) | not reported | [(17.24)](/filings/0000950170-25-066421.md) | [(22.00)](/filings/0000950170-25-104045.md) | [(0.92)](/filings/0001193125-25-275872.md) | not reported | [(0.83)](/filings/0001193125-26-213242.md) | [(0.87)](/filings/0001193125-26-338029.md) | [(0.88)](/filings/0001193125-25-275872.md) | not reported | [(0.95)](/filings/0001193125-26-213242.md) | [(0.63)](/filings/0001193125-26-338029.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [65.9](/filings/0000950170-24-125382.md) | [53.5](/filings/0000950170-25-043837.md) | [48.2](/filings/0000950170-25-066421.md) | [34.2](/filings/0000950170-25-104045.md) | [55.9](/filings/0001193125-25-275872.md) | [40.2](/filings/0001193125-26-100135.md) | [30.4](/filings/0001193125-26-213242.md) | [28.5](/filings/0001193125-26-338029.md) | [25.5](/filings/0001193125-25-275872.md) | [26.7](/filings/0001193125-26-338029.md) | [21.0](/filings/0001193125-26-213242.md) | [301](/filings/0001193125-26-338029.md) |
| Current assets | $m | not reported | [79.8](/filings/0000950170-25-043837.md) | not reported | [49.7](/filings/0001193125-24-209924.md) | [151](/filings/0000950170-24-125382.md) | [189](/filings/0001193125-26-100135.md) | [170](/filings/0000950170-25-066421.md) | [149](/filings/0000950170-25-104045.md) | [130](/filings/0001193125-25-275872.md) | [113](/filings/0001193125-26-338029.md) | [88.7](/filings/0001193125-26-213242.md) | [352](/filings/0001193125-26-338029.md) |
| Total assets | $m | not reported | [105](/filings/0000950170-25-043837.md) | not reported | [75.9](/filings/0001193125-24-209924.md) | [226](/filings/0000950170-24-125382.md) | [210](/filings/0001193125-26-100135.md) | [191](/filings/0000950170-25-066421.md) | [169](/filings/0000950170-25-104045.md) | [149](/filings/0001193125-25-275872.md) | [131](/filings/0001193125-26-338029.md) | [106](/filings/0001193125-26-213242.md) | [369](/filings/0001193125-26-338029.md) |
| Current liabilities | $m | not reported | [12.2](/filings/0000950170-25-043837.md) | not reported | [10.8](/filings/0001193125-24-209924.md) | [13.3](/filings/0000950170-24-125382.md) | [12.3](/filings/0001193125-26-100135.md) | [12.2](/filings/0000950170-25-066421.md) | [10.8](/filings/0000950170-25-104045.md) | [11.1](/filings/0001193125-25-275872.md) | [13.1](/filings/0001193125-26-338029.md) | [10.9](/filings/0001193125-26-213242.md) | [14.6](/filings/0001193125-26-338029.md) |
| Total liabilities | $m | not reported | [50.7](/filings/0000950170-25-043837.md) | not reported | [50.6](/filings/0001193125-24-209924.md) | [24.6](/filings/0000950170-24-125382.md) | [22.9](/filings/0001193125-26-100135.md) | [22.5](/filings/0000950170-25-066421.md) | [20.4](/filings/0000950170-25-104045.md) | [19.6](/filings/0001193125-25-275872.md) | [21.0](/filings/0001193125-26-338029.md) | [18.1](/filings/0001193125-26-213242.md) | [21.1](/filings/0001193125-26-338029.md) |
| Shareholders' equity | $m | [(151)](/filings/0000950170-24-125382.md) | [(162)](/filings/0001193125-26-100135.md) | [(175)](/filings/0001193125-25-275872.md) | [(191)](/filings/0001193125-25-275872.md) | [201](/filings/0001193125-25-275872.md) | [187](/filings/0001193125-26-338029.md) | [169](/filings/0001193125-26-338029.md) | [149](/filings/0001193125-26-338029.md) | [129](/filings/0001193125-25-275872.md) | [110](/filings/0001193125-26-338029.md) | [87.8](/filings/0001193125-26-338029.md) | [348](/filings/0001193125-26-338029.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.7) d](/filings/0000950170-24-125382.md) | [(10.7) d](/filings/0000950170-25-043837.md) | [(15.1)](/filings/0000950170-25-066421.md) | [(13.7) d](/filings/0000950170-25-104045.md) | [(11.6) d](/filings/0001193125-25-275872.md) | [(14.7) d](/filings/0001193125-26-100135.md) | [(19.8)](/filings/0001193125-26-213242.md) | [(23.0) d](/filings/0001193125-26-338029.md) | [(19.2) d](/filings/0001193125-25-275872.md) | [(14.7) d](/filings/0001193125-26-100135.md) | [(21.0)](/filings/0001193125-26-213242.md) | [(20.4) d](/filings/0001193125-26-338029.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000950170-24-125382.md) | [0.6 d](/filings/0000950170-25-043837.md) | [0.0](/filings/0000950170-25-066421.md) | [0.5 d](/filings/0000950170-25-104045.md) | [0.1 d](/filings/0001193125-25-275872.md) | [0.1 d](/filings/0001193125-26-100135.md) | [0.5](/filings/0001193125-26-213242.md) | [1.1 d](/filings/0001193125-26-338029.md) | [0.6 d](/filings/0001193125-25-275872.md) | [0.4 d](/filings/0001193125-26-100135.md) | [0.2](/filings/0001193125-26-213242.md) | [0.4 d](/filings/0001193125-26-338029.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-06-30) | period not labelled (2023-09-30) | period not labelled (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.8](/filings/0001193125-24-209924.md) | [7.0](/filings/0000950170-24-125382.md) | [0.8](/filings/0000950170-25-066421.md) | [0.8](/filings/0000950170-25-104045.md) | [18.9](/filings/0001193125-25-275872.md) | [24.3](/filings/0001193125-26-213242.md) | [24.4](/filings/0001193125-26-338029.md) | [24.5](/filings/0001193125-25-275872.md) | [24.7](/filings/0001193125-26-213242.md) | [39.4](/filings/0001193125-26-338029.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 48,890,121 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338029.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.